Searched for
TEVA PHARMA INDUSTRIES
Sun Pharma shares rally 9% in two days after $12-bn Organon deal. Here's what Morgan Stanley, other brokerages saySun Pharmaceutical Industries' shares surged nearly 9% after announcing the $11.75 billion acquisition of Organon & Co., a global leader in...- Natco Pharma launches additional strengths of generic version of Revlimid in USNatco Pharma Ltd on Friday said it has launched additional strengths for its generic lenalidomide capsules used in the treatment of multipl...
- Marksans Pharma acquires Teva's manufacturing site in GoaThe manufacturing site is spread across 47,597 sq meters and has approvals to manufacture products from EU, Health Canada and Japanese Heal...
- Sun may have better served by boarding global pharma talentInduction of eminent Indian leaders as independent directors lends credibility, but lack of experts from industry is in contrast to local p...
- Pharma stocks bleed as US states file lawsuit against generic drug firmsLupin, Aurobindo Pharma, Dr Reddy’s, Glenmark, Wockhardt USA and Zydus have been named in the lawsuit.
- If Sun Pharma inspections come through, 2018 could be a turning point for Indian pharma: Amit Rajan, Prosfora Technology“We have to get our things in order for sterile manufacturing and Sun Pharma Halol plant is mostly on steriles.”
- US Court rules in favour of Mylan for Copaxone patents: NatcoIn December 2016, the US Patent and Trademark Office (PTO) had ruled in favour of Mylan and three patents related to Copaxone 40 mg/mL were...
- Teva’s hostile bid for Mylan: Deal could open up a $2-billion opportunity for pharma companiesAccording to experts, there is a possibility that the fruition of the deal will open up a $2-billion opportunity for Indian generic pharma ...
- Teva offers to buy Mylan for $40.1 billionTeva, the world’s biggest maker of generic medicines, offered $82 a share in cash and stock for Mylan, according to a statement.
- Teva may move court against Dr Reddy's for patent infringementThe Israeli drug maker already is involved in various legal battles with other drug firms over the patent litigations of Copaxone.
- Pharmaceutical firm Teva API to set up unit in Indore SEZ; to invest 1000 crorePharmaceutical firm Teva API India plans to invest about Rs 1,000 crore over the next five years in setting up of a formulation unit in the...
- Natco Pharma loses patent case against Teva Pharmaceutical Industries of anti-sclerosis drugNatco Pharma has lost a patent litigation against Israel's Teva Pharmaceutical Industries in the US over multiple sclerosis treatment drug,...
- Wyeth makes $960 mn claims on Protonix patent case: Sun PharmaSun Pharma said US-based Wyeth Pharma has sought damages worth $960 mn related to their ongoing patent dispute over generic version of Prot...
- Jeremy Levin named as next CEO of Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries Ltd named Jeremy Levin of Bristol-Myers Squibb Coto to replace Shlomo Yanai as chief executive officer.
- Teva to buy Taiyo stake for $460 million, bid for restTeva Pharmaceutical Industries Ltd agreed to buy 57% of Taiyo Pharmaceutical Industry Co Ltd. for $460 million and bid for the rest.
- Matrix drags Israeli co Teva to court over patent issueThe dust hasn’t settled yet on the Novartis case and another patent dispute has emerged in the pharma space.
- Teva, Glenmark call an end to patent disputeIsraeli generic major Teva and Mumbai-based Glenmark Pharmaceuticals have settled a patent dispute over various generic versions of Coreg -...
- Flamingo expands CRAM pact with Israel co TevaMumbai-based Flamingo Pharmaceuticals has expanded its CRAM (contract research and manufacturing) agreement with Israel’s Teva Pharmaceutic...
- Wyeth's 'nod' to Sun generic may be tacticalWyeth’s decision to issue a covenant ‘not-to-sue’ (CNS) to Sun Pharmaceutical Industries for seeking approval to sell its version of anti-d...
- Teva exploring prospects in Indian marketThe world’s largest generic drug maker Teva Pharmaceuticals is investigating the Indian market and examining what value proposition it can ...
Load More
